心房颤动治疗新方向——延迟钠电流阻滞剂雷诺嗪被引量：1

Late Sodium Current Inhibitor Ranolazine——A Novel Anti-atrial Fibrillation Drug

下载PDF

导出

摘要延迟钠电流阻滞剂雷诺嗪最初作为抗心绞痛药物使用,其抗心律失常作用逐渐显露。目前临床研究提示雷诺嗪存在抑制心房颤动的作用,而基础研究在一定程度上解释了雷诺嗪抗心房颤动的作用。雷诺嗪展示出的有效性及安全性使其成为有前景的新型抗心律失常药物。 Late sodium current inhibitor ranolazine was prescribed as anti-ischemia drug in the first place. However,more and more clinical researches revealed its capability in anti-arrhythmias especially suppressing atrial fibrillation. Furthermore,other studies might partially explained the mechanism in reducing atrial fibrillation. Both effectiveness and safety could guarantee ranolazine a promising future as a novel anti-arrhythmias drug.

作者贺鹏康周菁

机构地区北京大学第一医院心内科

出处《心血管病学进展》 CAS 2015年第1期1-3,共3页 Advances in Cardiovascular Diseases

关键词雷诺嗪心房颤动延迟钠电流阻滞剂新型抗心律失常药物 ranolazine atrial fibrillation late sodium current inhibitor novel anti-arrhythmias drug

分类号 R541.75 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献23

1Camm A J, Kirchof P, Lip GY, et al. Guidelines for the management of atrial fibrillation, the task force for the management of atrial fibrillation of the Europe- an Society of Cardiology (ESC) [J]. Eur Heart J, 2010,31:2369-2429.
2CAST Investigators. Preliminary report: effect of encainide and fleeainide on mortality in a randomized trial of arrbythmia suppression after myocardial infarc- tion[J]. N Engl J Med, 1989,321:406-412.
3Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current" [ J]. Pharmacol Ther, 2008,119:326-339.
4Roden DM. Repolarization reserve : a moving target [ J ]. Circulation, 2008, 118:981-982.
5Wu L, Rajamani S, Li H, et al. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na( + ) current in the heart[ J]. Am J Physial Heart Circ Physiol, 2009,297 :H1048-1057.
6Bonatti R, Silva AF, Batatinha JA, et al. Selective late sodium current block- ade with GS-458967 markedly reduces ischemia-induced atrial and ventricular repolarization alternans and ECG heterogeneity[J]. Heart Rhythm, 2014,11: 1827-1835.
7Chaitman BR, Skettino SL, Parker JO, et al. Anti-isehemic effects and long- term survival during ranolazine monotherapy in patients with chronic severe angi- na[J]. J Am Coil Cardiol, 2004,43:1375-1382.
8Louis AA, Manousos IR, Coletta AP, et al. Clinical trials update: the Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT Ⅱ and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. Enhancing recovery in coronary heart disease pa- tients. Assessment of cardioversion using transoesophageal echocardiography. Azimilide post-infarct survival evaluation. Randomised evaluation of mechanical assistance for treatment of chronic heart failure[ J]. Eur J Heart Fail, 2002,4 : 111-116.
9Pepine C J, Wolff AA. A controlled trial with a novel anti-ischemic agent, rano- lazine, in chronic stable angina pectoris that is responsive to conventional anti- anginal agents. Ranolazine Study Group[ J]. Am J Cardiol, 1999,84:46-50.
10Stone PH, Chaitman BR, Stocke K, et al. The anti-ischemic mechanism of ac- tion of ranolazine in stable ischemic heart disease [ J ]. J Am Coil Cardiol,2010,56:934-942.

二级参考文献20

1Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation [ J] .Ann N Y Acad Sci,2010,1188:78-86.
2Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS ex- pert Consensus Statement on catheter and surgical ablation of at- rial fibrillation : recommendations for personnel, policy, proce- dures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fi- brillation[ J] .Heart Rhythm ,2007,4 : 816-861.
3Wu L, Shryock JC, Song Y, et al.An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts [ J ]. J Pharmacol Exp Ther, 2006, 316:718-726.
4Belardinelli L, Lin G, Smith-Maxwell C, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses exper- imental arrhythmias[ J] .J Pharmacol Exp Ther,2013,344:23-32.
5Savelieva I, Carom J.Anti-arrhythmic drug therapy for atrial fibrilla- tion : current anti-arrhythmie drugs, investigational agents, and in- novative approaches [ J ]. Europace, 2008,10 : 647- 665.
6Burashuikov A, Antzelevitch C. Advances in the Pharmacological Treatment of Atrial Fibrillation [ J ]. Curr Med Lit Cardiol, 2010, 29 : 1-5.
7Burashnikov A,Di Diego JM,Zygmunt AC,et al.Atrium-selective sodi- um channel block as a strategy for suppression of atrial fibrillation:differences in sodium channel inactivation between atria and ventri- cles and the role of ranolazine [ J] .Circulation,2007,116:1449.
8The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report:effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction[ J] .N Engl J Med, 1989,321:406-412.
9Verrier RL, Kumar K, Nieminen T, et al.Mechanisms of ranolazine" s dual protection against atrial and ventricular fibrillation [ J ]. Eu- ropace,2013,5:317-324.
10Hawwa N, Menon V. Ranolazine: Clinical Applications and Thera- peutic Basis[ J] .Am J Cardiovasc Drugs,2013,13:5-16.